PRESS RELEASE

Q3 2023 — Press release

Q3 2023PDF · 11 pages310 KB
News Release
____________________________________________________________________________
Merck Announces Third-Quarter 2023 Financial Results
- 	Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines
- 	Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022;
Excluding LAGEVRIO, Growth Was 6%; Excluding LAGEVRIO and the Impact of
Foreign Exchange, Growth Was 8%
o 	KEYTRUDA Sales Grew 17% to $6.3 Billion; Excluding the Impact of Foreign
Exchange, Sales Also Grew 17%
o 	GARDASIL/GARDASIL 9 Sales Grew 13% to $2.6 Billion; Excluding the Impact
of Foreign Exchange, Sales Grew 16%
o 	LAGEVRIO Sales Grew 47% to $640 Million; Excluding the Impact of Foreign
Exchange, Sales Grew 51%
- 	GAAP EPS Was $1.86; Non-GAAP EPS Was $2.13
- 	Announced Collaboration Agreement With Daiichi Sankyo for Three Clinical-Stage ADC
Candidates
- 	Received FDA Approval of KEYTRUDA for Perioperative Treatment of Certain Patients
With NSCLC in Combination With Chemotherapy, Based on KEYNOTE-671 Trial
- 	Obtained FDA Priority Review of Biologics License Application for Sotatercept
- 	Presented Compelling Data at ESMO 2023 Congress, Including:
o 	Phase 3 KEYNOTE-671 Trial
o 	Phase 3 KEYNOTE-A39/EV-302 Trial Conducted in Collaboration With Seagen
and Astellas
- 	Initiating Phase 3 Trials in 2023 Across Multiple Therapeutic Areas, Including Oncology,
Cardiometabolic and Immunology
- 	Full-Year 2023 Financial Outlook:
o 	Raises and Narrows Expected Worldwide Sales Range To Be Between $59.7
Billion and $60.2 Billion, Including Negative Impact of Foreign Exchange of
Approximately 2 Percentage Points; Outlook Includes Approximately $1.3 Billion
of LAGEVRIO Sales
o 	Now Expects Non-GAAP EPS To Be Between $1.33 and $1.38, Including the
Negative Impact of Foreign Exchange of Approximately 6 Percentage Points;
Outlook Reflects Negative Impact From Upfront Charge of $5.5 Billion, or $1.70
per Share, Related to the Collaboration Agreement With Daiichi Sankyo
RAHWAY, N.J., Oct. 26, 2023 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the third quarter of 2023.
“Our strong results this quarter reflect our talented team’s commitment to bringing
forward important innovation and pursuing breakthroughs for all those who count on us,” said

-- 1 of 11 --

- 2 -
Robert M. Davis, chairman and chief executive officer, Merck. “We continue to push the
boundaries of science, making disciplined investments to augment our diverse pipeline and
applying our expertise to accelerate potentially transformative treatments to address patient
needs – including through our recently announced collaboration with Daiichi Sankyo. I am proud
of our progress as we continue to execute at the highest level and work to generate strong and
sustainable value, today and well into the future.”
Financial Summary
$ in millions, except EPS amounts
Third Quarter
2023 	2022 	Change
Change Ex-
Exchange
Sales 	$15,962 	$14,959 	7% 	9%
GAAP net income1 	4,745 	3,248 	46% 	56%
Non-GAAP net income that excludes certain items 1,2* 	5,427 	4,703 	15% 	22%
GAAP EPS 	1.86 	1.28 	45% 	55%
Non-GAAP EPS that excludes certain items 2* 	2.13 	1.85 	15% 	22%
*Refer to table on page 6.
Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming
dilution was $1.86 for the third quarter of 2023. Non-GAAP EPS was $2.13 for the third quarter
of 2023. The increases in GAAP and non-GAAP EPS in the third quarter versus the prior year
were primarily due to operational strength in the business, as well as $0.22 of charges recorded
in 2022 related to collaboration and licensing agreements with Moderna, Inc. (Moderna), Orna
Therapeutics (Orna) and Orion Corporation (Orion). The increase in GAAP EPS in the third
quarter of 2023 was also driven by the impacts of intangible asset impairment charges recorded
in 2022, compared with no such charges recorded in 2023, and lower losses from investments
in equity securities in 2023. The increases in both GAAP and non-GAAP EPS in the third
quarter were partially offset by the unfavorable impact of foreign exchange.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, as well as income and losses from investments in equity securities.
Year-to-date results can be found in the attached tables.
1 Net income attributable to Merck & Co., Inc.
2 Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior
to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this
release.

-- 2 of 11 --

- 3 -
Third-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Third Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
Total Sales 	$15,962 	$14,959 	7% 	9%
Pharmaceutical 	14,263 	12,963 	10% 	11%
Increase driven by growth in oncology,
vaccines, and virology due to sales of
LAGEVRIO, partially offset by diabetes.
Excluding LAGEVRIO, growth of 9%.
Excluding LAGEVRIO and unfavorable impact
of foreign exchange, growth of 10%.
KEYTRUDA 	6,338 	5,426 	17% 	17%
Growth driven by increased global uptake in
earlier-stage indications, including triple-
negative breast cancer (TNBC) and renal cell
carcinoma (RCC), and continued strong global
demand from metastatic indications.
GARDASIL /
GARDASIL 9 	2,585 	2,294 	13% 	16%
Growth due to strong demand, particularly in
China, and higher pricing in the U.S., partially
offset by public-sector buying patterns in the
U.S.
JANUVIA / JANUMET 	835 	1,133 	-26% 	-25%
Decline primarily due to generic competition in
several international markets, particularly in
Europe, and lower demand in the U.S.
PROQUAD, M-M-R II
and VARIVAX 	713 	668 	7% 	6% 	Growth largely due to higher pricing in the U.S.
LAGEVRIO 	640 	436 	47% 	51%
Growth largely attributable to higher demand in
Japan, partially offset by lower demand in
Australia and nonrecurrence of sales in the
U.K.
BRIDION 	424 	423 	0% 	0%
Relatively flat compared with prior year due to
higher demand in the U.S., offset by generic
competition primarily in Europe.
Lynparza* 	299 	284 	5% 	6%
Growth driven primarily by higher pricing in the
U.S. and increased demand in Latin America.
Lenvima* 	260 	202 	29% 	30%
Growth primarily due to higher demand in the
U.S. and certain international markets, and
timing of shipments in China.
VAXNEUVANCE 	214 	16 	***N/M 	N/M
Growth driven largely by continued uptake in
pediatric indication in the U.S. and launches in
Europe.
Animal Health 	1,400 	1,371 	2% 	2%
Growth primarily driven by higher pricing in
both Livestock and Companion Animal product
portfolios.
Livestock 	874 	829 	5% 	7%
Growth primarily due to higher pricing across
product portfolio, as well as higher demand for
ruminant, poultry and swine products.
Companion Animal 	526 	542 	-3% 	-4%
Decline primarily due to lower vet visits in the
U.S., partially offset by higher pricing. Sales of
BRAVECTO were $235 million and $241
million in the current and prior-year quarters,
respectively, which represented a decline of
3%.
Other Revenues** 	299 	625 	-52% 	-18%
Decline primarily due to impact of revenue
hedging. Excluding unfavorable impact of
foreign exchange, decline due to lower

-- 3 of 11 --

- 4 -
Third Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
revenue from third-party manufacturing
arrangements.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities.
***Not meaningful
Third-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Third Quarter 2023
Cost of sales 	$4,264 	$552 	$33 	$- 	$3,679
Selling, general and administrative 	2,519 	17 	40 	- 	2,462
Research and development 	3,307 	10 	- 	- 	3,297
Restructuring costs 	126 	- 	126 	- 	-
Other (income) expense, net 	126 	(24) 	- 	17 	133
Third Quarter 2022
Cost of sales 	$3,934 	$446 	$54 	$- 	$3,434
Selling, general and administrative 	2,520 	22 	26 	- 	2,472
Research and development 	4,399 	902 	1 	- 	3,496
Restructuring costs 	94 	- 	94 	- 	-
Other (income) expense, net 	429 	(26) 	- 	350 	105
GAAP Expense, EPS and Related Information
Gross margin was 73.3% for the third quarter of 2023 compared with 73.7% for the third
quarter of 2022. The decrease was primarily due to the unfavorable impact of foreign exchange,
higher LAGEVRIO sales, which have a low gross margin, and higher acquisition- and
divestiture-related costs. The gross margin decline was partially offset by lower revenue from
third-party manufacturing arrangements, lower manufacturing-related costs and the favorable
impact of product mix.
Selling, general and administrative (SG&A) expenses were $2.5 billion in both the third
quarters of 2023 and 2022, primarily reflecting increased promotional spending, offset by lower
administrative costs.
3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions of businesses, intangible asset impairment charges and expense or income related to changes in the
estimated fair value measurement of liabilities for contingent consideration. R&D expenses in the third quarter of 2022 include
intangible asset impairment charges of $887 million largely related to nemtabrutinib. Also includes integration, transaction and
certain other costs associated with acquisitions and divestitures, as well as amortization of intangible assets related to
collaborations and licensing arrangements.

-- 4 of 11 --

- 5 -
Research and development (R&D) expenses were $3.3 billion in the third quarter of
2023 compared with $4.4 billion in the third quarter of 2022. The decrease was primarily due to
charges recorded in 2022 of $887 million for intangible asset impairments, largely related to
nemtabrutinib, and $690 million for collaboration and licensing agreements with Moderna, Orna
and Orion. The decrease in R&D expenses was partially offset by higher compensation and
benefit costs in 2023, reflecting in part increased headcount, higher investments in discovery
research and early drug development and higher clinical development spending.
Other (income) expense, net, was $126 million of expense in the third quarter of 2023
compared with $429 million of expense in the third quarter of 2022, primarily due to lower net
losses from investments in equity securities.
The effective tax rate was 15.5% for the third quarter of 2023 compared with 9.2% in the
third quarter of 2022.
GAAP EPS was $1.86 for the third quarter of 2023 compared with $1.28 for the third
quarter of 2022.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 77.0% for both the third quarters of 2023 and 2022, due to
the unfavorable impact of foreign exchange, and higher LAGEVRIO sales, which have a low
gross margin, offset by lower revenue from third-party manufacturing arrangements, lower
manufacturing-related costs and the favorable impact of product mix.
Non-GAAP SG&A expenses were $2.5 billion in both the third quarters of 2023 and
2022, primarily reflecting increased promotional spending, offset by lower administrative costs.
Non-GAAP R&D expenses were $3.3 billion in the third quarter of 2023 compared with
$3.5 billion in the third quarter of 2022. The decrease was primarily due to charges of $690
million in 2022 related to collaboration and licensing agreements with Moderna, Orna and Orion.
The decrease in R&D expenses was partially offset by higher compensation and benefit costs in
2023, reflecting in part increased headcount, higher investments in discovery research and early
drug development and higher clinical development spending.
Non-GAAP other (income) expense, net, was $133 million of expense in the third quarter
of 2023 compared with $105 million of expense in the third quarter of 2022.
The non-GAAP effective tax rate was 15.0% for the third quarter of 2023 compared with
13.6% in the third quarter of 2022.
Non-GAAP EPS was $2.13 for the third quarter of 2023 compared with $1.85 for the
third quarter of 2022.

-- 5 of 11 --

- 6 -
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Pipeline and Portfolio Highlights
Merck continued to achieve regulatory and clinical milestones across its expansive
pipeline and portfolio. The company is initiating Phase 3 trials in 2023 in multiple therapeutic
areas, including oncology, cardiometabolic and immunology, and in new modalities. These
include investigational individualized neoantigen therapy V940 in combination with KEYTRUDA,
antibody-drug conjugate (ADC) MK-2870 and lysine-specific demethylase-1 inhibitor MK-3543
in oncology, oral PCSK9 inhibitor candidate MK-0616 in cardiovascular, and humanized
monoclonal antibody MK-7240 in immunology.
In oncology, the company received U.S. Food and Drug Administration (FDA) approval
of KEYTRUDA for the treatment of certain patients with resectable non-small cell lung cancer
(NSCLC) as a neoadjuvant/adjuvant treatment, the company’s eighth approval of KEYTRUDA in
earlier-stage cancer. The FDA also granted priority review to two supplemental New Drug
Applications (sNDAs): for WELIREG in certain previously treated patients with advanced RCC,
and for KEYTRUDA in cervical cancer. Notably, Merck presented compelling new data at the
European Society for Medical Oncology (ESMO) Congress 2023 that showcased the company’s
progress in earlier stages of cancers, its foundational position in metastatic disease and
continued momentum in its diverse oncology pipeline.
In cardiovascular disease, Merck received priority review from the FDA for a new
Biologics License Application (BLA) for sotatercept, the company’s novel investigational activin
signaling inhibitor for the treatment of adults with pulmonary arterial hypertension (PAH) (World
Health Organization Group 1), based on clinically meaningful results from the Phase 3
STELLAR trial. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date
of March 26, 2024. If approved, sotatercept would be the first in its class, bringing a novel
approach to address a rare and progressive disease of the pulmonary arteries. Merck’s
Third Quarter
$ in millions, except EPS amounts 	2023 	2022
EPS
GAAP EPS 	$1.86 	$1.28
Difference 	0.27 	0.57
Non-GAAP EPS that excludes items listed below2 	$2.13 	$1.85
Net Income
GAAP net income 1 	$4,745 	$3,248
Difference 	682 	1,455
Non-GAAP net income that excludes items listed below1,2 	$5,427 	$4,703
Excluded Items:
Acquisition- and divestiture-related costs 3 	$555 	$1,344
Restructuring costs 	199 	175
Loss from investments in equity securities 	17 	350
Net decrease (increase) in income before taxes 	771 	1,869
Estimated income tax (benefit) expense 	(89) 	(414)
Decrease (increase) in net income 	$682 	$1,455

-- 6 of 11 --

- 7 -
submission for sotatercept to the Committee for Medicinal Products for Human Use (CHMP) in
the European Union (EU) has also been completed.
Additionally, Merck entered into a collaboration agreement with Daiichi Sankyo for three
potentially first-in-class clinical-stage DXd ADCs for the treatment of multiple solid tumors, both
as monotherapy and/or in combination with other treatments. This collaboration with Daiichi
Sankyo will further augment and diversify Merck’s oncology pipeline.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Approved KEYTRUDA for Treatment of Patients With Resectable (T≥4
cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant
Treatment, Then Continued as Single Agent as Adjuvant Treatment After
Surgery, Based on Results From Phase 3 KEYNOTE-671 Trial
(Read
Announcement)
FDA Granted Priority Review to Merck’s Application for KEYTRUDA Plus
Concurrent Chemoradiotherapy as Treatment for Patients With Newly
Diagnosed High-Risk Locally Advanced Cervical Cancer, Based on Results
From Phase 3 KEYNOTE-A18 Trial; FDA Set PDUFA Date of Jan. 20, 2024
(Read
Announcement)
FDA Accepted for Priority Review Merck’s sNDA for WELIREG in Certain
Previously Treated Patients With Advanced RCC, Based on Results From
Phase 3 LITESPARK-005 Trial; FDA Set PDUFA Date of Jan. 17, 2024
(Read
Announcement)
European Commission (EC) Approved KEYTRUDA as Adjuvant Treatment
for Adults With NSCLC at High Risk of Recurrence Following Complete
Resection and Platinum-Based Chemotherapy, Based on Results From
Phase 3 KEYNOTE-091 Trial
(Read
Announcement)
EC Approved KEYTRUDA Plus Trastuzumab and Chemotherapy as First-
Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal
Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1), Based on
Results From Phase 3 KEYNOTE-811 Trial
(Read
Announcement)
EU Granted Positive CHMP Opinion for KEYTRUDA Plus Chemotherapy as
First-Line Treatment for HER2-Negative Advanced Gastric or GEJ
Adenocarcinoma Expressing PD-L1 (CPS ≥1), Based on Results From
Phase 3 KEYNOTE-859 Trial
(Read
Announcement)
Japan Ministry of Health, Labor and Welfare Approved Lynparza Plus
Abiraterone and Prednisolone for Treatment of BRCA-Mutated Metastatic
Castration-Resistant Prostate Cancer, Based on Results From Phase 3
PROpel Trial
(Read
Announcement)
KEYTRUDA Plus Chemotherapy Before Surgery and Continued as Single
Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative
Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC, Based on Results
From Phase 3 KEYNOTE-671 Trial
(Read
Announcement)
KEYTRUDA Plus Padcev Reduced Risk of Death by More Than Half Versus
Chemotherapy in Patients With Previously Untreated Locally Advanced or
Metastatic Urothelial Cancer, Based on Results From Phase 3 KEYNOTE-
A39/EV-302 Trial
(Read
Announcement)
KEYTRUDA Plus Concurrent Chemoradiotherapy Significantly Improved
Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy
Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer,
Based on Results From Phase 3 KEYNOTE-A18 Trial
(Read
Announcement)
WELIREG Significantly Improved PFS and Objective Response Rates
Versus Everolimus in Certain Previously Treated Patients With Advanced
RCC, Based on Results From Phase 3 LITESPARK-005 Trial
(Read
Announcement)
KEYTRUDA Plus Chemotherapy Showed Statistically Significant
Improvement in Pathological Complete Response Rate as Neoadjuvant
Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2-
Breast Cancer, Based on Results From Phase 3 KEYNOTE-756 Trial
(Read
Announcement)

-- 7 of 11 --

- 8 -
KEYTRUDA Plus Trastuzumab and Chemotherapy Significantly Improved
PFS Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive
Advanced Gastric or GEJ Adenocarcinoma, Based on Results From Phase
3 KEYNOTE-811 Trial
(Read
Announcement)
KEYTRUDA Significantly Improved Disease-Free Survival in Certain
Patients With Muscle-Invasive Urothelial Carcinoma After Surgery, Based
on Results From Phase 3 KEYNOTE-123 Trial
(Read
Announcement)
Cardiovascular
FDA Accepted for Priority Review a New BLA for Sotatercept, an Activin
Signaling Inhibitor to Treat Adults With PAH, Based on Results From Phase
3 STELLAR Trial; FDA Set PDUFA Date of March 26, 2024
(Read
Announcement)
Merck Presented New Analyses Supporting the Promising Potential of
Sotatercept, Its Investigational Medicine for Adults With PAH, Based on
Results From Phase 3 STELLAR and SOTERIA Trials
(Read
Announcement)
Merck Initiated Phase 3 Clinical Program for Oral PCSK9 Inhibitor
Candidate MK-0616
(Read
Announcement)
Vaccines Long-Term Follow-up Data on Sustained Immunogenicity and Safety for
GARDASIL Published in Pediatrics
(Read
Announcement)
Hospital Acute
Care
Merck Received Positive EU CHMP Opinion for PREVYMIS for Prevention
of CMV Disease in High-Risk Adult Kidney Transplant Recipients and
Extended 200-Day Dosing in Adult Hematopoietic Stem Cell Transplant
Recipients at Risk for Late CMV Infection and Disease, Based on Results
From Phase 3 P002 and P040 Trials
(Read
Announcement)
Sustainability Highlights
Merck issued its 2022/2023 Impact Report highlighting the company’s performance
across its sustainability efforts, reflecting strong progress toward its commitments to advance
access to health and operate responsibly. The report noted how the company reached more
than 500 million people around the world with its innovations in 2022 and expanded two of its
2025 Access to Health goals.
Full-Year 2023 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2023
Updated 	Prior
Sales * 	$59.7 to $60.2 billion 	$58.6 to $59.6 billion
Non-GAAP Gross margin 2 	Approximately 77% 	Approximately 77%
Non-GAAP Operating expenses 2** 	$39.8 to $40.4 billion 	$34.0 to $34.6 billion
Non-GAAP Other (income) expense, net 2 	Approximately $200 million 	Approximately $100 million
Non-GAAP Effective tax rate2*** 	39.0% to 40.0% 	30.5% to 31.5%
Non-GAAP EPS2**** 	$1.33 to $1.38 	$2.95 to $3.05
Share count (assuming dilution) 	2.55 billion 	2.55 billion
*Includes approximately $1.3 billion of LAGEVRIO sales. The company does not have any non-GAAP adjustments to sales.
**Includes an aggregate $17.1 billion of R&D expenses related to the Prometheus Biosciences, Inc. (Prometheus) and Imago
BioSciences, Inc. (Imago) acquisitions, and upfront payments for the license and collaboration agreement with Kelun-Biotech (a
holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd) and collaboration agreement with Daiichi Sankyo. Outlook does not
assume any additional significant potential business development transactions.
***Includes an approximate 24.5 percentage point negative impact related to business development (Imago, Prometheus and
Daiichi Sankyo).
****Includes $6.22 of one-time charges related to the Prometheus and Imago acquisitions and upfront payments to Kelun-Biotech
and Daiichi Sankyo.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax

-- 8 of 11 --

- 9 -
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the company’s future GAAP results.
Merck continues to experience strong sustained demand for key growth products,
particularly in oncology and vaccines. As a result, Merck is raising and narrowing its full-year
sales outlook. Merck now expects full-year sales to be between $59.7 billion and $60.2 billion,
including a negative impact of foreign exchange of approximately 2 percentage points, at mid-
October 2023 exchange rates. This full-year outlook includes approximately $1.3 billion of
LAGEVRIO sales.
Merck’s full-year non-GAAP effective income tax rate is expected to be between 39.0%
and 40.0%, which includes an approximate 24.5 percentage point negative impact related to
business development activity.
Merck now expects its full-year non-GAAP EPS to be between $1.33 and $1.38,
including a negative impact of foreign exchange of approximately 6 percentage points, at mid-
October 2023 exchange rates. This revised non-GAAP EPS range reflects the following, which
were not previously included in the outlook:
• 	Additional strength in the business of approximately $0.15 per share.
• 	A pretax charge of $5.5 billion, or $1.70 per share, for the collaboration agreement with
Daiichi Sankyo.
• 	Estimated expense in the fourth quarter of 2023 of approximately $0.04 per share to
advance the ADC assets and finance the transaction with Daiichi Sankyo.
• 	A 1%, or approximately $0.05 per share, incremental negative impact of foreign
exchange.
The non-GAAP EPS range excludes acquisition- and divestiture-related costs, costs
related to restructuring programs, income and losses from investments in equity securities, and
a previously disclosed charge related to settlements with certain plaintiffs in the Zetia antitrust
litigation.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Thursday, Oct. 26, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
prepared remarks and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (888) 769-8514 (U.S. and Canada Toll-Free)
or (517) 308-9208 and using the access code 8206435.

-- 9 of 11 --

- 10 -
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the
impact of pharmaceutical industry regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022,
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).

-- 10 of 11 --

- 11 -
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WELIREG (belzutifan)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 11 of 11 --